Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
COMMENTARY
Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
To read the full story
Related Article
- Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- MHLW Panel Recommends Lifting Ban on Cannabis-Derived Drugs, Eyes Legal Amendment Next Spring
June 15, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
COMMENTARY
- Alzheimer’s Pipeline Looks Past Amyloid to Earlier Intervention, Tau Targets
October 28, 2026
- Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026
- Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
October 6, 2026
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…